Open AccessEffectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
Author(s) -
Andrea Gori,
Andrea Antinori,
Alessandra Vergori,
Maria Vittoria Cossu,
Barbara Menzaghi,
Gaetana Sterrantino,
Stefano Rusconi,
Anna Maria Cattelan,
Francesco Castelli,
Nicola Gianotti,
Giancarlo Orofino,
Diego Ripamonti,
Stefano Savinelli,
Elio Manzillo,
Teresa Santantonio,
Benedetto Maurizio Celesia,
Roberto Cauda,
Renato Maserati,
Antonella d’Arminio Monforte,
Christof Stingone,
Stefano Bonora,
Alessia Uglietti,
Roberta Termini,
Francesco Rucci,
Daniela Mancusi
Publication year - 2020
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000002331
Subject(s) - darunavir , regimen , ritonavir , medicine , cobicistat , tolerability , adverse effect , gastroenterology , clinical endpoint , viral load , prospective cohort study , human immunodeficiency virus (hiv) , virology , antiretroviral therapy , randomized controlled trial
This study investigates the effectiveness and tolerability of switching to a darunavir/cobicistat (DRV/c)-based antiretroviral regimen from a ritonavir-boosted protease inhibitor (PI/r)-based regimen in virologically suppressed HIV-positive patients. DRV trough values were also investigated.